IG
IGC.L
—
London Stock Exchange
Biotechnology & Life-Science Tools
India Capital Growth Fund Ltd
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$0,28
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
India Capital Growth Fund Ltd is a closed-end fund that invests in a diversified portfolio of equities, primarily in India, with the objective of generating capital growth for its shareholders.
Business. India Capital Growth Fund Ltd (IGC.L) is a biotechnology and life-science tools company listed on the London Stock Exchange. The firm operates within the Health Care sector, focusing on activities related to biotechnology and life-science tools. Specific details regarding its operating segments and geographic presence are not disclosed. The company is headquartered in the United Kingdom, consistent with its primary listing location.
Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target4,00
Analyst recommendations
2 analysts · consensus BuyBuy2
Hold0
Sell0
12-month price target
4,00
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
2 analysts · indicative
Ownership→
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability
—
not yet wired
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to IGC.L. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ2 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
India Capital Growth Fund Ltd (IGC.L) is a biotechnology and life-science tools company listed on the London Stock Exchange. The firm operates within the Health Care sector, focusing on activities related to biotechnology and life-science tools. Specific details regarding its operating segments and geographic presence are not disclosed. The company is headquartered in the United Kingdom, consistent with its primary listing location.
Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
AI synthesis
GENERATEDIndia Capital Growth Fund Ltd operates with a capital structure that is not fully disclosed, as liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The fund's shares outstanding are equal in both basic and diluted terms, indicating no dilution risk from stock options or convertible securities. However, the lack of liquidity data makes it difficult to assess the fund's ability to meet short-term obligations or respond to market volatility.
Profitability and returns for the fund are not quantifiable at this time, as no specific metrics such as return on equity or net asset value per share are provided in the available data. The fund's performance relative to industry benchmarks or cohort medians cannot be determined without further financial disclosures.
The fund's geographic exposure is concentrated in India, as indicated by its investment strategy, but the exact distribution of revenue or assets across segments or regions is not disclosed. This lack of transparency limits the ability to assess the fund's diversification and exposure to regional economic risks.
Growth trajectory for the fund is also unclear, as no revenue history or outlook for the current or next fiscal year is available. The absence of numerical deltas or directional guidance makes it difficult to project future performance or assess the fund's ability to adapt to changing market conditions.
Risk factors include the inability to assess liquidity risk, which could impact the fund's ability to meet redemption requests or manage cash flow. The fund is also subject to market risk, as its performance is tied to the equity markets in India. However, dilution risk is currently low, as there is no evidence of potential share issuance or convertible instruments that could dilute existing shareholders.
Recent events or filings that could impact the fund's operations or strategy are not disclosed in the available data. The absence of recent transcripts or regulatory filings limits the ability to assess management's strategic direction or response to external challenges.
Key takeaways
- India Capital Growth Fund Ltd is a closed-end fund focused on Indian equities, with a high classification confidence.
- The fund's capital structure and liquidity risk cannot be assessed due to missing balance-sheet data and lack of going-concern language.
- Profitability and returns are not quantifiable, and no industry benchmarks are available for comparison.
- The fund's geographic exposure is concentrated in India, but segment or regional revenue distribution is not disclosed.
- Growth trajectory and future performance are uncertain due to the absence of revenue history and outlook data.
- Dilution risk is currently low, but liquidity risk remains unassessed, which could impact the fund's operational flexibility.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation FY
Market price
$169,00
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
—
Net cashⓘ
—
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
—
ROEⓘ
—
Cash conversionⓘ
—
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs IGC · multiples and returns
IQ
IQV—
Iqvia Holdings Inc
$181,94
30,9B USDP/E
22,7x
— vs self
Div yield
—
— vs self
ROE
21,9 %
+89,6 vs self
CR
CRL—
Charles River Laboratories
$230,87
11,4B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-4,6 %
+63,2 vs self
ME
MEDP—
Medpace Holdings Inc
$576,00
16,7B USDP/E
34,4x
— vs self
Div yield
—
— vs self
ROE
75,4 %
+143,1 vs self
AL
ALKS—
Alkermes PLC
$49,53
8,2B USDP/E
39,8x
— vs self
Div yield
—
— vs self
ROE
8,4 %
+76,1 vs self
PI
PIII—
P3 Health Partners Inc
$10,20
73,8M USDP/E
—
— vs self
Div yield
—
— vs self
ROE
95,3 %
+163,0 vs self
OR
ORGO—
Organogenesis Holdings Inc
$2,38
306,2M USDP/E
9,0x
— vs self
Div yield
—
— vs self
ROE
8,5 %
+76,3 vs self
NA
NAGE—
Niagen Bioscience Inc
$3,53
281,1M USDP/E
17,4x
— vs self
Div yield
—
— vs self
ROE
22,7 %
+90,4 vs self
SP
SPRY—
Ars Pharmaceuticals Inc
$5,51
547,1M USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-149,9 %
-82,2 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-0,08
Predicted surprise
+0,00
Beat probability
45 %
Analysts
2
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-08 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$3,00
Mean$4,00
Median$4,00
High$5,00
Spot$169,00
−97.6 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskUnknown
Benchmarks vs cohort
No cohort benchmark data available for this issuer yet.
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 6 488 462 sh11 exercises · 9 grants5 insiders
- Director, CEO · Options → Common StockDisposed 323 077 @ $0,26exercise · 2026-04-01
- Director, CEO · Restricted Stock Units → Common StockDisposed 16 667exercise · 2026-04-01
- Director, CEO · Restricted Stock Units → Common StockDisposed 33 332exercise · 2026-04-01
- Director · Restricted Stock Units → Common StockDisposed 70 000exercise · 2026-04-01
- Director · Restricted Stock Units → Common StockDisposed 80 000exercise · 2026-04-01
- Director · Restricted Stock Units → Common StockDisposed 100 000exercise · 2026-04-01
- Director, CEO · Restricted Stock Units → Common StockDisposed 333 333exercise · 2026-04-01
- Director, PFO · Restricted Stock Units → Common StockDisposed 100 000exercise · 2026-04-01
- Director, PFO · Options → Common StockDisposed 138 462 @ $0,26exercise · 2026-04-01
- Director · Restricted Stock Units → Common StockDisposed 50 000exercise · 2026-04-01
- Director, CEO · Restricted Stock Units → Common StockAcquired 16 667grant · 2026-02-03
- Director, CEO · Restricted Stock Units → Common StockAcquired 66 666grant · 2026-02-03
- Director · Restricted Stock Units → Common StockDisposed 100 000exercise · 2026-01-19
- Director, CEO · Options → Common StockAcquired 1 500 000grant · 2025-10-17
- Director · Options → Common StockAcquired 750 000grant · 2025-10-17
- Director · Options → Common StockAcquired 500 000grant · 2025-10-17
- Director · Options → Common StockAcquired 500 000grant · 2025-10-17
- Director, PFO · Options → Common StockAcquired 1 000 000grant · 2025-10-17
- Director, PFO · Options → Common StockAcquired 500 000grant · 2025-10-17
- Director, CEO · Options → Common StockAcquired 3 000 000grant · 2025-10-17
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Source documents
- India Capital Growth Fund Ltd Market data — financials · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Ram MukundaPresident, Chief Executive Officer, Director
Insider activity
Mixed / flat0 buys · 0 sellsnet $04 insiders · last 365d
- Director, CEO · Common StockOther 2 226 475 @ $0,27$601K · 2026-06-30
- Director, PFO · Common StockOther 2 048 378 @ $0,27$553K · 2026-06-30
- Director, CEO · Common StockOther 333 333 · 2026-04-01
- Director · Common StockOther 100 000 · 2026-04-01
- Director, PFO · Common StockOther 138 462 @ $0,26$36K · 2026-04-01
- Director, PFO · Common StockOther 100 000 · 2026-04-01
- Director · Common StockOther 50 000 · 2026-04-01
- Director · Common StockOther 80 000 · 2026-04-01
- Director, CEO · Common StockOther 33 332 · 2026-04-01
- Director, CEO · Common StockOther 16 667 · 2026-04-01
- Director, CEO · Common StockOther 323 077 @ $0,26$84K · 2026-04-01
- Director · Common StockOther 70 000 · 2026-04-01
- Director, CEO · Common StockOther 50 000 · 2026-02-03
- Director · Common StockOther 100 000 · 2026-01-19
- Director, PFO · Common StockOther 50 000 · 2025-10-17
- Director, CEO · Common StockOther 100 000 · 2025-10-17
Short positioning
208.1Kshares short-82.3% vs prior
1days to cover
12.4%short of daily vol
1.7Kfails-to-deliver
as of 2026-06-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
IGC.LCanonical
London Stock Exchange · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskUnknown
Evidence & claims
From filings & derived data- Debt-to-equity (FY 2025-12-31): 0.31xDerived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -2.2%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -18.8%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 91.5%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.83xDerived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 18.6%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 7.0%Derived (calculated)
- Shares outstanding (annual): 95.04MSEC XBRL filing
- Total assets (annual): USD 9.71MSEC XBRL filing
- Current assets (annual): USD 1.79MSEC XBRL filing
- Long-term debt (annual): USD 131KSEC XBRL filing
- Shareholders' equity (annual): USD 7.42MSEC XBRL filing
- Current liabilities (annual): USD 2.16MSEC XBRL filing
- Total liabilities (annual): USD 2.29MSEC XBRL filing
- Cash & equivalents (annual): USD 900KSEC XBRL filing
- Revenue (YoY) (2025-03-31 vs 2024-03-31): -5.5%Derived (calculated)
- Net income (YoY) (2025-03-31 vs 2024-03-31): 45.2%Derived (calculated)
- Capex (YoY) (2025-03-31 vs 2024-03-31): -18.8%Derived (calculated)
- EPS (diluted) (YoY) (2025-03-31 vs 2024-03-31): 59.1%Derived (calculated)
- EPS (basic) (YoY) (2025-03-31 vs 2024-03-31): 59.1%Derived (calculated)
- Gross profit (YoY) (2025-03-31 vs 2024-03-31): -15.6%Derived (calculated)
- Cost of revenue (YoY) (2025-03-31 vs 2024-03-31): 6.5%Derived (calculated)
- R&D expense (YoY) (2025-03-31 vs 2024-03-31): -3.1%Derived (calculated)
- Net margin (FY 2025-03-31): -560.3%Derived (calculated)
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ2 2026 earnings (expected) estimated date
2026-07-29 22:34 UTCEVENTHa Price Listing IGC remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 260 consecutive trading days (last close $0.2622). cure deadline 2027-01-17 (172 days remaining).
2026-07-07 04:39 UTCFILINGMaterial 8-K
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-30INSIDERMukunda Ram transacted 2.23M sh — Director, CEO ~$601k
2026-06-30INSIDERGRIMALDI CLAUDIA transacted 2.05M sh — Director, PFO ~$553k
2026-04-01 00:00 UTCINSIDER20 insider transactions — 2026-04 · net buy $120k 10 derivative
2026-04-01 00:00 UTCINSIDER20 insider transactions — 2026-04 · net buy $120k 10 derivative
2026-04-01INSIDERMukunda Ram transacted 333.3k sh — Director, CEO
2026-04-01INSIDERPRINS RICHARD K transacted 100.0k sh — Director
2026-04-01INSIDERGRIMALDI CLAUDIA transacted 138.5k sh — Director, PFO ~$36k
2026-04-01INSIDERGRIMALDI CLAUDIA transacted 100.0k sh — Director, PFO
2026-04-01INSIDERMoran James P transacted 50.0k sh — Director
2026-04-01INSIDERMoran James P transacted 80.0k sh — Director
2026-04-01INSIDERMukunda Ram transacted 33.3k sh — Director, CEO
2026-04-01INSIDERMukunda Ram transacted 16.7k sh — Director, CEO
2026-04-01INSIDERMukunda Ram transacted 323.1k sh — Director, CEO ~$84k
2026-04-01INSIDERPRINS RICHARD K transacted 70.0k sh — Director
2026-04-01INSIDERMoran James P disposed of 50.0k sh Restricted Stock Units — Director
2026-04-01INSIDERGRIMALDI CLAUDIA disposed of 100.0k sh Restricted Stock Units — Director, PFO
2026-04-01INSIDERGRIMALDI CLAUDIA disposed of 138.5k sh Options — Director, PFO
2026-04-01INSIDERMukunda Ram disposed of 33.3k sh Restricted Stock Units — Director, CEO
2026-04-01INSIDERMukunda Ram disposed of 16.7k sh Restricted Stock Units — Director, CEO
2026-04-01INSIDERMukunda Ram disposed of 323.1k sh Options — Director, CEO
2026-04-01INSIDERMukunda Ram disposed of 333.3k sh Restricted Stock Units — Director, CEO
2026-04-01INSIDERPRINS RICHARD K disposed of 70.0k sh Restricted Stock Units — Director
2026-04-01INSIDERPRINS RICHARD K disposed of 100.0k sh Restricted Stock Units — Director
2026-04-01INSIDERMoran James P disposed of 80.0k sh Restricted Stock Units — Director
2026-02-03 00:00 UTCINSIDER3 insider transactions — 2026-02 2 derivative
2026-02-03 00:00 UTCINSIDER3 insider transactions — 2026-02 2 derivative
2026-02-03INSIDERMukunda Ram transacted 50.0k sh — Director, CEO
2026-02-03INSIDERMukunda Ram acquired 66.7k sh Restricted Stock Units — Director, CEO
2026-02-03INSIDERMukunda Ram acquired 16.7k sh Restricted Stock Units — Director, CEO
2026-01-19 00:00 UTCINSIDER2 insider transactions — 2026-01 1 derivative
2026-01-19 00:00 UTCINSIDER2 insider transactions — 2026-01 1 derivative
Showing the 40 most recent of 60 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage